Insys Update: Stunning Numbers, Devastating Results
By: Jason Marcewicz | Content and Communications Specialist | Advanced Medical Strategies
The pharmaceutical company Insys Therapeutics has been in the news a lot recently—and for all the wrong reasons. Last September AMS reported about Insys’ schemes to sell more of their pain drug Subsys to unwitting physicians. Now, it seems that Insys didn’t just try to fool doctors into prescribing more Subsys, but also enticed them into entering lucrative kickback arrangements. The result? America’s opioid crisis. Our follow-up article looks at the stunning numbers: the payouts and payoffs, as well as the subsequent price gouging of the very people Insys helped become addicted to their product.